Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.
Otros episodios de "Kidney360"



No te pierdas ningún episodio de “Kidney360”. Síguelo en la aplicación gratuita de GetPodcast.








